GRAIL, LLC (GRAL)vsNatera Inc (NTRA)
GRAL
GRAIL, LLC
$61.64
-2.03%
HEALTHCARE · Cap: $2.69B
NTRA
Natera Inc
$194.24
-11.64%
HEALTHCARE · Cap: $30.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 1467% more annual revenue ($2.31B vs $147.17M). NTRA leads profitability with a -9.0% profit margin vs -277.5%. GRAL earns a higher WallStSmart Score of 36/100 (F).
GRAL
Hold36
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 39.8% year-over-year
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -16.1% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 15.8x book value
0.0% earnings growth
ROE of -14.3% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book. Revenue growth of 14.0% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
GRAL profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA is growing revenue faster at 39.8% — sustainability is the question.
NTRA generates stronger free cash flow (38M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GRAL scores higher overall (36/100 vs 31/100) and 14.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a leading biotechnology innovator specializing in groundbreaking blood tests for early cancer detection, leveraging its proprietary genomic technologies to transform the multi-cancer early detection (MCED) landscape. By providing individuals with crucial insights for proactive health management, GRAIL is committed to advancing precision medicine and significantly improving patient outcomes. The company's pioneering efforts aim to fill critical gaps in existing cancer screening and diagnostics, solidifying its position as a vital entity in the evolving oncology sector.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?